Regulators at the U.S. Food and Drug Administration on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity.

On Monday, the Food and Drug Administration approved a pill version of Wegovy, Novo Nordisk’s wildly popular weight loss drug, officially launching the first oral GLP-1 medication ever cleared for obesity treatment.

Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for obesity.

In the studies the company submitted to the FDA, people who took the daily Wegovy pill lost about the same amount of weight—around 16.6% of their body mass—as those who gave themselves weekly Wegovy injections for just over a year. Read More: How a Nobel-Winning Researcher Transformed Cancer Treatments With His Lifesaving Curiosity

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the FDA for approval on Thursday.

Global pharma giants Eli Lilly and Novo Nordisk are scrambling to cement their lead in India's booming obesity drug market before cheaper generic versions hit

Global pharmaceutical leaders Eli Lilly and Novo Nordisk are intensifying competition in Indias rapidly expanding obesity drug market as they race to secure dominance before lower-cost generic alternatives arrive in